Navigation Links
Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Date:1/7/2008

ALISO VIEJO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that CEO Ron Andrews is scheduled to participate in the OneMedPlace Emerging Healthcare Technologies Finance Forum. Andrews will make a presentation at 1:50 p.m. PST on Monday, January 7 and participate in a panel discussion on Personalized Medicine at 3:00 p.m. PST on Tuesday, January 8. The forum will be held January 7-8 at the Sir Francis Drake Hotel in Union Square in San Francisco.

A webcast of the presentation will be available on Friday, January 11, 2008 at http://www.onemedplace.com.

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.

The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
2. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
3. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
4. Siemens Building Technologies Helping Companies Participate in EPA Labs21 Movement With Comprehensive Compliance Solution Strategy
5. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
8. Angiotech to participate in RBC 2007 Healthcare Conference
9. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Lev Pharmaceuticals Invites You to Participate in its Q307 Earnings Results Conference Call and Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...DPharmaceuticalsInc.announced,theUSPatent&Trad...itsnano-particleoraldeliveryorNODtechnology. ,,...ratepeptidesor,proteinsintobio-adhesivenano-partic...edasinjections.NODtechnologyisaplatformtechnology,...ulin,interferon,growthhormone,exenatide,heparinan...
(Date:11/24/2009)...anghaiBiolaxyannouncedthe,ChineseStateFood&Dru...lnewdrugapplication(IND)foritsoralinsulinproject,(...tes.ThisIND,approvalallowsBiolaxytoinitiateitsfirs...aracteristicofhighbloodglucoseandpoor,metabolism.T...and,macro-vasculardiseases,lossofvision,kidneyfail...
(Date:11/24/2009)...pproved the Promega PowerPlex 16 HS System for use...A records for the National DNA Index System. , ...he FBI recently approved the Promega PowerPlex&re...ting in, or generating DNA records for, the Nation...s more than seven million profiles and has assiste...
(Date:11/24/2009).../PRNewswire-FirstCall/-HamiltonThorneLtd.(TSX-V:HT...vancedlasersystemsandinstrumentsforthestemcellrese...onalandfinancialresultsforthethirdquarterendedSept...46millioncomparedwith$1.43millioninQ32008,-Grosspr...3,2008,-Netlossreducedto$148,000comparedto$283,000...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7
...and product pipeline, BOTHELL, WA and VANCOUVER, ...euticals, Inc. (NASDAQ: OGXI ), a biopharmaceutic...cialization of new therapies that address,unmet ne...udited financial,results for the third quarter and...rter 2008 Financial Results, On August 21, 2008, ...
...hua-PRNewswire/ -- Simcere Pharmaceutical,Group (N...f branded generic,pharmaceuticals and innovative a...China market, announced today its participation in... 2008. The conference will be held at,the Mandarin...cere,s chief financial officer, Frank Zhigang Zhao...
...0 InspireMD, developers of,the novel MGuard(TM) c...TM),was successfully implanted in a complex lesion...erformed by Dr. Dariusz Dudek and was broadcast,fr...fast Meeting Symposium,"A New Approach to Treating...as met with great enthusiasm and excitement. Some ...
Other Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4
(Date:11/25/2009)...he course of a lifetime, the heart pumps some 250 ...rder to do this, the muscle fibers of the heart ha...ded by Dr. Wolfgang Rottbauer, vice chair of the D... Hospital (Chairman: Prof. Dr. H. A. Katus), has d...ability of the smallest muscular unit, the sarcome...
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)...ists have crystallised a protein that may help gut...protein could be used by probiotic producers to id...it to people. , "Probiotics need to interact with... and if they attach to surfaces in the gut they ar... their activity," says Dr Nathalie Juge from the I...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2New PICC Mimics Nature 50488 1New PICC Mimics Nature 50488 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Press Ganey Launches Community Image Solution 50480 1Press Ganey Launches Community Image Solution 50480 2Press Ganey Launches Community Image Solution 50480 3
.... , Infectious proteins known as prions have bee...E). The culprits are "incorrectly folded" proteins... bases for such prion diseases are not yet fully u...others are not? A team headed by Beat Meier (ETH Z...f Bordeaux, France) has examined two different for...
... Montreal, 13 June 2008 Researchers at the McG...sity and the University of British Columbia (UBC) ... cause an increase in serious adverse events, but ...s adverse events. , Several drugs containing com...noids, are available for medical purposes in Canad...
... discovered that a protein previously shown to hav...he formation of cysts in Autosomal Dominant Polycy...n life-threatening genetic diseases and has shown...isease in mice. , The discovery was published ...ine yesterday. , The team showed that a pro-in...
Other Biology News:Tracking prions 2Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
...apidly and reliably amplify unknown genomic DNA u... hassle-free, ready-to use components, at an extra...ients are provided in each kit. The Genome Walking...g of genomic DNA, isolating promoter and regulator...
Rabbit Anti-Human YIPF6 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Calf serum from Equitech-Bio
Agarose-LE from Ambion
Biology Products: